Decision guide

How to Pick a European Biotech Partner in 2026: Decision Guide

Picking a European biotech partner in 2026 is not a generic search - it is a sequence of narrow decisions, each with a different shortlist. The Memel Biotech directory surfaces roughly 330 operators across ten European countries and nine categories. The right partner depends on four things: what you are buying (modality + service scope), what scale you need (clinical vs. commercial), which geography fits regulatory and logistics constraints, and which directory entries have the public track record to justify shortlisting. This brief is the decision hub that maps each question to the underlying landscape brief, category page, or compliance filter. Use it as the entry point; drop into the deeper brief or directory page for each axis you are actively evaluating.

Summary

Key findings

For biologics manufacturing at scale, the primary European shortlist is Lonza (Switzerland), Rentschler Biopharma (Germany), Vetter Pharma (Germany, sterile fill-finish), FUJIFILM Diosynth Denmark, and AGC Biologics (Denmark + Germany). The European CDMO Capacity 2026 brief is the right deeper read.
For mRNA and immunotherapy, the European innovation layer concentrates in Germany (BioNTech Mainz, CureVac Tübingen, AGC Biologics Heidelberg, IDT Biologika, BioSpring Frankfurt) with Swiss API capacity (Bachem). The European mRNA & Immunotherapy 2026 brief covers the full supply chain.
For viral vector CDMO (AAV, adenoviral, lentiviral), the European CDMO layer is narrow - FinVector, Kuopio Center for Gene and Cell Therapy, 3PBIOVIAN, IDT Biologika, and Fuse Vectors (platform-stage). The Viral Vector CDMO Europe 2026 brief is the deeper read.
For CRO and clinical services, Biomapas (Kaunas) is the Baltic full-service anchor with CEE coverage; ICON, Medpace, and Pratia operate pan-European from Warsaw and Munich. The Baltic CRO Landscape 2026 brief covers the Baltic CRO layer in detail.
First-pass shortlist

Choose the partnership type before making a shortlist

“Biotech partner” can mean an external manufacturer, a CRO, a discovery specialist, a therapeutic collaborator, or a logistics provider. Start with the work that must be delivered, then use the linked detailed guide and each operator’s primary sources to verify programme fit.

External manufacturing

A CDMO or drug-product manufacturer

Switzerland, Germany, Denmark, Finland, and the Baltics

Publicly stated scope
Start with the European CDMO Capacity guide, then route by modality: integrated biologics, sterile fill-finish, viral vector, peptide or oligonucleotide API, or a smaller regional manufacturing route.
Confirm first
Modality, development phase, scale, drug substance or drug product scope, analytics, technology transfer, quality-system expectations, named manufacturing site, and available campaign route.
Do not assume
That a company’s general CDMO description confirms the needed product presentation, current availability, or an acceptable manufacturing path.
Clinical or research services

A CRO, preclinical partner, or discovery-services provider

Europe-wide

Publicly stated scope
Use the European CRO and Drug Discovery Services guides to separate multi-country clinical operations from preclinical pharmacology, medicinal chemistry, DMPK, ADMET, bioanalysis, and biospecimen work.
Confirm first
Exact work package, therapeutic area, model or protocol, countries and sites, GxP expectations, data deliverables, team ownership, and the programme decision the work must support.
Do not assume
That a CRO label proves full-service trial delivery, a validated scientific model, or adequate expertise for the programme.
Specialised modality

A narrow technology, platform, or advanced-therapy route

Germany, Nordics, Switzerland, Poland, and the Baltics

Publicly stated scope
Use the dedicated mRNA, viral-vector, cell-and-gene-therapy, antibody, diagnostics, or discovery brief before approaching a specialist operator.
Confirm first
Whether the operator is a service partner, a product developer, or a platform company; the exact modality; regulatory stage; IP model; evidence package; manufacturing dependencies; and the intended collaboration structure.
Do not assume
That a technology platform or therapeutic pipeline is available for external service work, licensing, or a partnership in the needed geography.
Commercial or therapeutic collaboration

A company with an internal pipeline, product, or licensing position

Europe-wide

Publicly stated scope
Use condition and modality pages to identify companies whose publicly stated pipeline or commercial products match the indication, then approach them as potential collaborators rather than vendors.
Confirm first
Pipeline stage and current status, rights and territory, collaboration precedent, therapeutic overlap, evidence maturity, decision-maker, and whether the company is actively seeking external partnerships.
Do not assume
That a publicly listed programme, product, or city location indicates an open licensing or co-development opportunity.
Supply chain and infrastructure

A GDP logistics, laboratory-supply, or research-infrastructure partner

Pan-European

Publicly stated scope
Use the logistics and regional landscape guides for the supporting route when the programme depends on temperature-controlled movement, samples, reagents, cleanroom access, academic research, or an incubator environment.
Confirm first
Material classification, temperature and chain-of-custody needs, origin and destination, customs or release-testing handoffs, storage, validation evidence, lead times, and the responsible legal entity.
Do not assume
That a directory presence or regional coverage confirms a qualified shipment lane, available laboratory space, or a facility suitable for the programme.
Numbers

Quick numbers

Operators in the directory~330Across 10 countries + 9 categories
Biologics CDMO core5 anchorsLonza, Rentschler, Vetter, FUJIFILM, AGC
Viral vector CDMO layer5 operators4 operating + 1 platform-stage
Landscape briefs8CDMO, mRNA, viral vector, CRO, Poland, Baltic, German, Swiss vs German
Analysis

The four-decision framework

Partner selection in 2026 runs through four decisions, each narrowing the directory shortlist. First: what are you buying? The category page is the first filter - CDMO, CRO, Manufacturing, Research, Diagnostics, Drug Discovery, Genomics, Tools, or Regulatory Anchor. Second: what scale? Clinical-stage optionality sits with mid-cap specialists (Baltic, Finnish, Polish operators); commercial-scale depth concentrates in Switzerland and Germany. Third: which geography? EU-internal for regulatory simplicity (Germany, Poland, Baltics, Nordics); Switzerland with EU-aligned logistics and higher-cost brand-heavy operators; the Nordics for vaccine and immunotherapy specialties. Fourth: which operators have the public track record? The directory entry shows leadership, source-backed facility, quality-system declarations, and latest review timestamp - three independent signals that let a sponsor shortlist before a single outreach email.

Analysis

Biologics manufacturing: Lonza, Rentschler, Vetter, FUJIFILM, AGC

For clinical-to-commercial biologics, the European shortlist is tight. Lonza (Visp, Switzerland) anchors large-integrated biologics + ADC + cell and gene therapy. Rentschler Biopharma (Laupheim, Germany) is the mid-to-large biologics CDMO with a published regulatory track record. Vetter Pharma (Ravensburg, Germany) operates at large commercial scale for sterile fill-finish. FUJIFILM Diosynth Denmark (Hillerod) runs mammalian biologics manufacturing. AGC Biologics operates across Heidelberg (Germany) + Soborg (Denmark). These five form the core European biologics CDMO shortlist. The Swiss vs German Biotech Manufacturing 2026 brief has the Switzerland/Germany decision rule, and the European CDMO Capacity 2026 brief covers the full CDMO landscape.

Analysis

mRNA, gene therapy, and specialised modalities

For mRNA drug substance, BioNTech (Mainz) operates commercial-scale in-house; CureVac (Tübingen) runs a clinical-development RNA platform; AGC Biologics Heidelberg provides mRNA + pDNA CDMO services. For viral vector, the European CDMO layer is specific: FinVector (Kuopio, clinical-to-commercial AAV and adenoviral), Kuopio Center for Gene and Cell Therapy (GMP AAV, adenovirus, lentivirus), 3PBIOVIAN (biologics + viral vectors + pDNA), IDT Biologika (viral vectors alongside viral vaccines), and Fuse Vectors (pre-GMP platform-stage cell-free AAV). For peptides and oligonucleotides, Bachem (Switzerland) and BioSpring (Germany). The European mRNA & Immunotherapy 2026 and Viral Vector CDMO Europe 2026 briefs cover each layer in detail.

Analysis

CRO and clinical services

European clinical research organisations run from two axes. The pan-European CRO network (ICON, Medpace, Pratia, plus the wider Evotec research-services layer) operates from Warsaw, Munich, Frankfurt, and Hamburg. The Baltic CRO cluster (Biomapas in Kaunas, Cureline Baltic in Vilnius, Inpharmatis in Riga, Asper Biogene and BioCC in Tartu) offers EU-internal nearshore capacity at lower cost. For sponsors, the choice is scope (full-service pan-European vs. specialised Baltic) and cost. The Baltic CRO Landscape 2026 brief covers the Baltic layer; the Polish Biotech Landscape 2026 brief covers Warsaw CRO operations.

Analysis

Discovery services, drug-discovery partners, and research

For drug discovery services, Selvita (Kraków) is the CEE contract research organisation for medicinal chemistry, biology, and DMPK, with development services downstream. Evotec (Hamburg) operates integrated drug discovery pan-European. For tools + reagents, Eppendorf (Hamburg), Miltenyi Biotec (Bergisch Gladbach), QIAGEN (Hilden), Thermo Fisher Scientific Baltics (Vilnius) + Thermo Fisher Supply sites cover the European research-tools layer. For academic + translational anchor research, EMBL Heidelberg, DKFZ, Max Delbrück Center Berlin, Vilnius University Life Sciences Center, Estonian Genome Center, and Latvian Institute of Organic Synthesis are the directory’s research infrastructure. The Polish Biotech Landscape 2026, Baltic Biotech Landscape 2026, and German Biotech Landscape 2026 briefs cover regional discovery + research depth.

Analysis

Geography and regulatory fit

EU-internal operations (Germany, Poland, Baltics, Nordics) remove cross-regulatory overhead and use the same CTIS + EMA + GDP rails. Switzerland is outside the EU but operationally integrated - uses GDP-aligned logistics, interfaces with EMA through established pathways, and is often perceived by sponsors as carrying higher pharma brand weight alongside higher operating costs. UK (not in this directory’s scope) requires separate regulatory planning post-Brexit. For Nordic countries, vaccine and immunotherapy specialties concentrate in Denmark (Bavarian Nordic MVA-BN, ALK-Abelló allergen immunotherapy, Statens Serum Institut) and Sweden (Valneva Sweden, plus the Karolinska-adjacent Solna therapeutics layer). The European mRNA & Immunotherapy 2026 brief covers the Nordic vaccine layer.

Analysis

Supply chain: logistics, reagents, supporting infrastructure

Biotech partner selection is incomplete without the supply-chain check. GDP-certified pharmaceutical logistics runs through DHL Life Sciences & Healthcare (four German sites: Bonn, Florstadt, Leipzig/Halle, Rheinbach), Kuehne+Nagel Healthcare (two German sites plus Poland and Netherlands operations), and World Courier (Vilnius, Warsaw, and pan-European coverage). Reagent and consumables supply runs through Thermo Fisher Scientific (Vilnius + Warsaw), Avantor / VWR (Darmstadt + Poland). For any European partner engagement, the GDP-logistics link and reagent-supply link from the partner’s site to the rest of the sponsor’s footprint is the integrity check that determines whether the partnership is operational in practice, not just on paper. The Baltic-German supply chain brief maps the pan-European supply-chain geography.

Analysis

How to shortlist before outreach

Before contacting any operator, run three checks against the directory entry. First, the source-backed facility: directory entries link to the official company page with a physical address and at least one public facility reference. If the directory cannot cite a facility source, the operator is not ready for sponsor outreach. Second, the leadership layer: named, identifiable executives with track records. Anonymous LLC fronts fail this check. Third, the latest review timestamp: the directory records when each entry was last verified, and stale entries (more than 12 months old) should be re-checked independently before shortlisting. Once an operator clears these three checks, the deeper landscape brief for the relevant modality gives the sponsor a factual baseline before the first phone call.

What to watch

What to watch next

Capacity expansion announcements from Lonza, Rentschler, Vetter, FUJIFILM Denmark, AGC Biologics
New European viral vector CDMO entrants - most likely spin-outs from existing biologics CDMOs
EU Biotech Act implementation effect on biomanufacturing funding and partner-selection dynamics
Baltic and Polish CRO capacity scaling up into commercial-phase trial operations
Cross-regulatory coordination announcements (Swissmedic ↔ EMA ↔ FDA) for 2026–2027 launches
FAQ

Frequently asked questions

Where do I start if I need a European biologics CDMO?

Start with the European CDMO Capacity 2026 brief. For biologics, the core European shortlist is Lonza (Visp, Switzerland), Rentschler Biopharma (Laupheim, Germany), Vetter Pharma (Ravensburg, Germany, sterile fill-finish), FUJIFILM Diosynth Denmark (Hillerod), and AGC Biologics (Heidelberg + Soborg). The Swiss vs German Biotech Manufacturing 2026 brief has the Switzerland / Germany decision rule.

Where do I start if I need a European viral vector CDMO?

Start with the Viral Vector CDMO Europe 2026 brief. The narrow European shortlist is FinVector (Kuopio, clinical-to-commercial AAV + adenoviral), Kuopio Center for Gene and Cell Therapy (AAV + adenovirus + lentivirus), 3PBIOVIAN (Turku, biologics + viral vectors + pDNA), IDT Biologika (Dessau-Rosslau, viral vectors alongside viral vaccines), and Fuse Vectors (Copenhagen, pre-GMP platform-stage cell-free AAV).

Where do I start if I need a European CRO?

For full-service pan-European CRO work, ICON Germany (Frankfurt), Medpace Germany (Munich), Medpace Poland (Warsaw), Pratia Poland (Warsaw), and ICON Poland (Warsaw) are the main directory entries. For Baltic CRO capacity at nearshore cost, Biomapas (Kaunas), Cureline Baltic (Vilnius), Inpharmatis (Riga), Asper Biogene (Tartu), and BioCC (Tartu). The Baltic CRO Landscape 2026 brief covers the Baltic layer in detail; the Polish Biotech Landscape 2026 brief covers Warsaw CRO operations.

How do I decide between Switzerland, Germany, Denmark, and the Baltics?

Switzerland for large-integrated biologics and peptide / oligonucleotide API (Lonza, Bachem), with higher operating costs and EU-aligned logistics; Germany for breadth + depth of CDMO, mRNA, and big pharma anchors (Rentschler, Vetter, BioNTech); Denmark for non-German biologics CDMO (FUJIFILM, AGC) and the Nordic vaccine + immunotherapy layer (Bavarian Nordic, ALK-Abelló); the Baltics for EU-internal nearshore capacity (Northway Biotech, Biomapas) at lower operating cost. The four country / region landscape briefs - Swiss vs German, Baltic, German, Polish - cover each geography in detail.

How can I tell if a directory entry is ready for outreach?

Three checks. First, the facility source: does the entry cite an official company page with a physical address? Second, the leadership: are executives named and publicly identifiable? Third, the last verification date: if it is more than 12 months old, re-verify independently before outreach. The Memel Biotech verification methodology page describes the review process in detail.

Methodology note

Sources and interpretation

Sources: every Memel Biotech landscape brief referenced here plus the underlying verified directory entries. This brief is an editorial hub - the factual claims are grounded in the individual landscape briefs and the directory operator records they cite.

Disclaimer

Use limits

This brief is a decision-framework overview for orientation. It does not certify any specific operator as fit for a specific programme - every partner selection requires direct verification of capability, capacity, regulatory posture, and references.

Primary sources

Source list

Memel Biotech verification methodologyMemel Biotech listing review policyEU Clinical Trials Regulation (CTIS)European Medicines AgencyEU Biotech and Biomanufacturing Hub
Related pages

Related directory records

Verification methodologyLithuania biotech page (LT)
Briefs

Continue through related topics.

A useful brief should help people move into related records, cities, categories, and methodology pages without falling back into generic template language.

All briefsDirectory home